Greenland Capital Management LP
Position in TEVA — Teva Pharmaceutical Industries Ltd
CIK 1896430
NEW YORK, NY
Position in TEVA
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$3,237,900
-$304,435 QoQ
Shares Held
107,500
-5.3% QoQ
Ownership
0.009%
of shares outstanding
% of Portfolio
0.77%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2024
4 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in TEVA Over Time
Shares Held
Position Value (USD)
Derivatives in TEVA
reported options exposure · as of Dec 31, 2024CallValue
$551,000
CallShares
25,000
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Mar 31, 2026Greenland Capital Management LP holds $8,898,900 across 2 Drug Manufacturers - Specialty & Generic names. TEVA ranks #2 (36.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LQDA |
Liquidia Corp
|
150,000 | $5,661,000 | |
| 2 | TEVA |
Teva Pharmaceutical Industries Ltd
This page
|
107,500 | $3,237,900 |
All Filings in TEVA
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $3,237,900 | 107,500 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $3,542,335 | 113,500 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $2,546,149 | 126,047 | Shares | Sole | 2025-11-10 | |
| 2024-12-31 | $551,000 | 25,000 | Call | Sole | 2025-02-13 | |
| 2024-12-31 | $440,800 | 20,000 | Shares | Sole | 2025-02-13 | |
| No filing history on record for this holder in this stock. | ||||||